109221-90-1

Basic information

• Product Name: 3-Benzyloxyphenylhydrazine hydrochloride
• Synonyms: (3-PHENOXY-PHENYL)-HYDRAZINE HYDROCHLORIDE;N'-(3-PHENOXY-PHENYL)-HYDRAZINIUM, CHLORIDE;3-BenzyloxyphenylhydrazineHcl;3-Benzyloxyphenylhydrazine hydrochloride;D1181
• CAS NO: 109221-90-1
• Molecular Formula: C₁₂H₁₂N₂O*ClH
• Molecular Weight: 250.72
• EINECS: 604-604-1
• Mol File: 109221-90-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 420.2°C at 760 mmHg
• Flash Point: 208°C
• Appearance: /
• Vapor Pressure: 1.83E-07mmHg at 25°C
• CAS DataBase Reference: 3-Benzyloxyphenylhydrazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzyloxyphenylhydrazine hydrochloride(109221-90-1)
• EPA Substance Registry System: 3-Benzyloxyphenylhydrazine hydrochloride(109221-90-1)

Safety Data

• Hazardous Substances Data: 109221-90-1(Hazardous Substances Data)

Usage

General Description

3-Benzyloxyphenylhydrazine hydrochloride is a chemical compound used primarily for research and scientific purposes. This synthetic compound is typically handled as a crystalline solid with a white to light yellow coloration. It's also known for solubility in water and other polar solvents. Though it is not widely used outside of the scientific and research community, 3-Benzyloxyphenylhydrazine hydrochloride has been instrumental in pharmaceutical development, often in reactions required to produce novel drugs and chemical compounds. As with many chemicals of this nature, it must be handled with care due to its potential reactivity.

InChI:InChI=1/C13H14N2O.ClH/c14-15-12-7-4-8-13(9-12)16-10-11-5-2-1-3-6-11;/h1-9,15H,10,14H2;1H

Upstream product

• 3586-12-7 3-phenoxyaniline 

Downstream Products

• 1189198-33-1 methyl 2-(3-phenoxyphenyl) hydrazinecarboxylate 

Relevant articles and documents

Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis

Based on a previous study and in silico molecular docking experiments, we have designed and synthesized a new series of ten 5-Alkoxy-N-3-(3-PhenoxyPhenyl)-1,3,4-Oxadiazol-2(3H)-one derivatives (RmPPOX). These molecules were further evaluated as selective and potent inhibitors of mammalian digestive lipases: purified dog gastric lipase (DGL) and guinea pig pancreatic lipase related protein 2 (GPLRP2), as well as porcine (PPL) and human (HPL) pancreatic lipases contained in porcine pancreatic extracts (PPE) and human pancreatic juices (HPJ), respectively. These compounds were found to strongly discriminate classical pancreatic lipases (poorly inhibited) from gastric lipase (fully inhibited). Among them, the 5-(2-(Benzyloxy)ethoxy)-3-(3-PhenoxyPhenyl)-1,3,4-Oxadiazol-2(3H)-one (BemPPOX) was identified as the most potent inhibitor of DGL, even more active than the FDA-approved drug Orlistat. BemPPOX and Orlistat were further compared in?vitro in the course of test meal digestion, and in?vivo with a mesenteric lymph duct cannulated rat model to evaluate their respective impacts on fat absorption. While Orlistat inhibited both gastric and duodenal lipolysis and drastically reduced fat absorption in rats, BemPPOX showed a specific action on gastric lipolysis that slowed down the overall lipolysis process and led to a subsequent reduction of around 55% of the intestinal absorption of fatty acids compared to controls. All these data promote BemPPOX as a potent candidate to efficiently regulate the gastrointestinal lipolysis, and to investigate its link with satiety mechanisms and therefore develop new strategies to “fight against obesity”.